PI3キナーゼ (PI3K) のシグナリング経路分析：ベストセラー薬の特許失効および下流ターゲットへ向かう開発により、変化する市販薬・パイプライン製品の情勢
PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets
|出版日||ページ情報||英文 265 Pages
|PI3キナーゼ (PI3K) のシグナリング経路分析：ベストセラー薬の特許失効および下流ターゲットへ向かう開発により、変化する市販薬・パイプライン製品の情勢 PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets|
|出版日: 2018年07月01日||ページ情報: 英文 265 Pages||
当レポートでは、PI3キナーゼ (PI3K) のシグナリング経路の様々な構成要素へ作用する市販薬・パイプライン製品について包括的に調査し、疾病における役割を含めたPI3K経路の重要性に関する議論、およびPI3K市販薬・パイプライン製品の情勢などについて分析しています。
Phosphoinositide 3-kinases (PI3K) are a family of lipid kinases that transduce signals from a range of growth factors and cytokines into intracellular messages by generating phospholipids. This in turn activates the serine/threonine kinase AKT (AKT), as well as other downstream effectors such as mammalian target of rapamycin (mTOR) and forkhead box O (FOXO).
The PI3K pathway is a critical signal transduction pathway and plays important roles in the regulation of many cellular processes including protein synthesis, cell-cycle progression and cell survival. Additionally, numerous diseases are known to be associated with dysregulated PI3K signaling. This is particularly the case for cancers, with the pathway being recognized as perhaps the most commonly activated signaling pathway in human cancer. However, PI3K signaling has also been associated with several other disease areas including disorders of the gastrointestinal, metabolic and central nervous systems.
Due to its wide-ranging role in numerous cellular processes and disease states, the PI3K signaling pathway has been extensively researched over recent decades and is widely recognized as a prime target for therapeutic intervention. Indeed, globally, 1,984 products that target components of the PI3K signaling network have gained market approval to date. These include a number of highly clinically and commercially successful therapies such as the blockbuster drugs Herceptin (trastuzumab), Avastin (bevacizumab) and Lantus (insulin glargine).
Despite this, PI3K signaling remains a focal point of drug discovery as many components of the pathway are yet to be targeted by currently available pharmaceuticals. There are 2,061 pipeline products in development that target components of the PI3K pathway, many of which act on first-in-class molecular targets.
The latest report, "PI3K Signaling Pathway Analysis" provides a comprehensive assessment of the marketed and pipeline products acting on various components of the phosphoinositide 3-kinase (PI3K) signaling network. The report discusses the significance of the PI3K pathway, including its role in disease, and provides a comprehensive overview of the PI3K marketed and pipeline landscapes. The report provides a breakdown of the following key signaling pathways within the PI3K network in terms of marketed and pipeline activity: PI3K/AKT/mTOR pathway, Ras/Raf/MEK/ERK pathway, cell survival pathways downstream of AKT, cell-cycle progression pathways downstream of AKT, metabolism pathways downstream of AKT and kinases downstream of phosphoinositide-dependent kinase-1 (PDK1).
An analysis of the marketed and pipeline activity across various nodes (defined as groups of molecules which have the same role in response to a stimulus) within each of these pathways is provided. An examination of the marketed and pipeline products acting on each of these pathways in terms of molecule type and therapy area, and, in the case of pipeline products, novelty and stage of development, provides further granularity. Additionally, detailed product profiles of key marketed products are provided, which incorporate clinical and commercial perspectives and include historical and forecast annual sales revenues. The report concludes with a discussion of promising late-stage pipeline products.